Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Down 11.8% in December

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 438,500 shares, a decline of 11.8% from the November 30th total of 497,300 shares. Based on an average trading volume of 93,300 shares, the short-interest ratio is currently 4.7 days. Currently, 3.8% of the shares of the stock are sold short.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Trading Down 3.6 %

AWH stock traded down $0.03 during trading on Friday, hitting $0.74. 149,503 shares of the company’s stock were exchanged, compared to its average volume of 76,360. The stock has a market capitalization of $12.37 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. Aspira Women’s Health has a 52-week low of $0.67 and a 52-week high of $5.65. The business has a 50-day moving average price of $0.82 and a two-hundred day moving average price of $1.02.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Aspira Women’s Health in a research note on Wednesday. They issued a “hold” rating for the company.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.